The molecular rationale for the use of antiangiogenic therapy is based on the results of studies showing that increased levels of vascular endothelial growth factor (VEGF) in ovarian cancer were associated with increased resistance to chemotherapy and a poorer prognosis [79]. Here, VEGFA is linked to ovarian cancer.